Travere Therapeutics names Bradley Campbell CEO, effective Dec. 1, 2026
Bitget2026/09/21 20:05- Travere Therapeutics named Bradley L. Campbell as president, CEO, board member, effective Dec. 1, 2026.
- Outgoing CEO Eric Dube will serve until that date, then remain executive advisor through Feb. 15, 2027.
- Campbell previously led Amicus Therapeutics as president and CEO; held commercial, business development roles at Genzyme, Bristol-Myers Squibb.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitmine Buys 9,587 ETH as Holdings Near 5% of Ethereum Supply
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
Crypto prices
More
